Kodiak Sciences reported a wider-than-expected loss of $1.03 per share in Q2 2025, missing the Zacks Consensus Estimate of $1.01 and higher than the 86 cents loss per share in the same quarter last year. The company, which currently lacks approved products, has yet to generate revenues, with research and development expenses increasing by 32% to $42.8 million in the reported quarter due to heightened clinical activities. Conversely, general and administrative expenses decreased by 18% to $12.8 million, primarily driven by lower non-cash stock-based compensation expenses.
As of June 30, 2025, Kodiak had $104.2 million in cash, cash equivalents, and marketable securities, down from $138.9 million three months prior. The company believes this balance is sufficient to support its present and future operations through 2026. Despite a 13.4% year-to-date decrease in share value, Kodiak remains focused on pipeline development.
Kodiak is currently evaluating tarcocimab in diabetic retinopathy patients and KSI-501 in retinal vascular diseases. The company aims to release top-line data for the tarcocimab study in Q1 2026 and for the DAYBREAK study, exploring wet AMD treatment, in Q3 2026. Pending the success of these pivotal studies, Kodiak plans to submit a regulatory filing seeking approval for tarcocimab in diabetic retinopathy, wet AMD, and retinal vein occlusion.
Additionally, Kodiak has initiated phase III studies for KSI-101, its third investigational candidate targeting macular edema. This bispecific protein aims to address inflammation and angiogenesis by targeting IL-6 and VEGF. The company anticipates top-line results from the PEAK and PINNACLE studies in late 2026 or early 2027.
In comparison to Kodiak, other biotech companies like CorMedix, Zymeworks, and Alvotech have shown positive developments. CorMedix’s earnings per share estimates for 2025 and 2026 have increased, with a 49.1% share price rally year to date. Zymeworks has narrowed its per-share loss estimates for 2025 and 2026, with a 4.8% stock decline in 2025. Alvotech has seen an increase in earnings per share estimates for both years, despite a 32.3% stock dip year to date.
Overall, Kodiak Sciences’ financial results reflect ongoing investments in research and development, with a focus on advancing its pipeline of innovative therapies for various eye diseases. The company’s upcoming data readouts and regulatory plans underscore its commitment to delivering potentially impactful treatments to patients in need.
Key Takeaways:
– Kodiak Sciences reported a wider loss than expected in Q2 2025, driven by increased research and development expenses.
– The company’s pipeline includes promising candidates like tarcocimab and KSI-501 for retinal diseases, with pivotal study results expected in 2026.
– Kodiak aims to seek regulatory approval for tarcocimab in diabetic retinopathy, wet AMD, and retinal vein occlusion based on study outcomes.
– Other biotech companies like CorMedix, Zymeworks, and Alvotech have also shown positive trends in earnings estimates and stock performance.
Tags: regulatory, biotech
Read more on finance.yahoo.com